Generalisation from phase III clinical trials: Survival, quality of life, and health economics

Lancet

Volumn 350, Issue 9083, 1997, Pages 1025-1027

  Fayers, P M ^a   Hand, D J ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER SURVIVAL; CLINICAL RESEARCH; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; METHODOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SHORT SURVEY; SURVIVAL; TREATMENT OUTCOME;

EID: 0030810515     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03053-5     Document Type: Note

References (31)

1. Bailey KR. Generalizing the results of randomized clinical trials. Control Clin Trials 1994; 15: 15-23.
2. Rubins HB. From clinical trials to clinical practice: generalizing from participant to patient. Control Clin Trials 1994; 15; 7-10.
3. Davis CE. Generalizing from clinical trials. Control Clin Trials 1994; 15: 11-14.
4. Wittes J. Introduction: from clinical trials to clinical practice - four papers from a plenary session. Control Clin Trials 1994; 15: 5-6.
5. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995; 345: 1616-19.
6. Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994; 70; 352-62.
7. Stiller CA. Survival of patients with cancer. BMJ 1989; 299: 1058-59.
8. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognosis factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991; 9: 818-26.
9. Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratorna: does referral to a specialist unit matter? Lancet 1993; 341: 999-1002.
10. Horwitz RI, Singer BH, Makuch RW, Viscoli CM. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. J Clin Epidemiol 1996; 49: 395-400.
11. Sørenson TIA. Which patients may be harmed by good treatments? Lancet 1996; 348: 351-52.
12. Fayers PM. Can overall results of clinical-trials be applied to all patients? Lancet 1995; 346: 445-56.
13. Hays RD, Sherbourne CD, Bozzette SA. Pharmacoeconomics and quality of life research beyond the randomized clinical trial. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippinncott-Raven, 1996: 155-59.
14. Cunningham WE, Bozzette SA, Hays RD, Kanouse DE, Shapiro MF. Comparison of health-related quality of life in clinical trial and non-clinical trial HIV infected cohorts. Med Care 1995; 33: AS15-25.
15. Bouchet C, Guillemin F, Briancon S. Nonspecific effects in longitudinal studies: impact on quality of life measures. J Clin Epidemiol 1996; 49: 15-20.
16. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1987.
17. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant tradiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996; 88: 1039-45.
18. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300: 1458-60.
19. Brennes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer therapy. Eur J Cancer 1995; 31A: 1955-59.
20. O'Connor AM. Effects of framing and level of probability on patients' preferences for cancer chemotherapy. J Clin Epidemiol 1989; 42: 119-26.
21. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Cummings BJ. Whose utilities for decision-analysis? Med Decis Making 1990; 10: 58-67.
22. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 330-40.
23. Drummond MF. Economic analysis alongside clinical trials: Problems and potential. J Rheumatol 1995; 22: 1403-07.
24. Buxton MJ. National Wilms' tumor study: economic perspective. Monogr Natl Cancer Inst 1955; 19: 27-29.
25. Gulati SC, Bitran JD. Cost-effective analysis: sleeping with an enemy or a friend? J Clin Oncol 1995; 13: 2152-54.
26. Freund DA, Dittus RS. Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukaemia: economic evaluation with attention to inpatient and outpatient resource utilization. Monogr Natl Cancer Inst 1995; 19: 37-40.
27. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance - issues in the design and analysis of stochastic cost-effectiveness studies in health-care. Med Care 1994; 32: 150-63.
28. Bennett CL, Smith TJ, George SL, Hillner BE, Fleishman S, Niell HB. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 1995; 13: 2457-63.
29. Drummond MF, O'Brien BJ. Economic analysis alongside clinical trials: practical considerations J Rheumatol 1995; 22: 1418-19.
30. Rittenhouse BE, O'Brien BJ. Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd edn. Philadelphia: Lippincott-Raven, 1996: 1215-23.
31. Spiegelhalter DJ, Gore SM, Fitzpatrick R, Fletcher AE, Jones DR, Cox DR. Quality of life measures in health care-III: resource allocation. BMJ 1992; 305: 1205-09.